Relief Therapeutics Holding AG (RLFTF)

[changes_iv]

WHY WOULD THE FDA WITHHOLD EUA APPROVAL OF ZYESAMI (TM)???

On Wednesday, the United Kingdom became the first country to clear the Pfizer vaccine. Over the past week, FDA Commissioner Stephen Hahn has been called to the White House twice to explain why the vaccine could not be authorized more quickly. Those urging speed point to the two-dose vaccine’s incredibly strong short-term efficacy — it prevents 95% of symptomatic Covid-19 cases, at least based on a few months’ data — and that it appears safe overall.

With more than 2,000 Americans dying from Covid-19 daily, they argue, what was the risk of trying it sooner?

The FDA has said in multiple public forums that it could not have moved any faster. The agency’s staff “were eating turkey sandwiches on Thanksgiving while reviewing documents,” Peter Marks, who heads the FDA center conducting the vaccine reviews, said on a Thursday webcast run by the Journal of the American Medical Association.

https://www.statnews.com/2020/12/04/how-key-decisions-slowed-fdas-review-of-covid-19-vaccine-but-also-gave-it-important-data/

CAN THE BEST OF VACCINES, ANTIVIRALS, THERAPEUTICS DO WHAT SAFE AND EFFECTIVE ZYESAMI (TM) (AVIPTADIL) CAN DO??? PHARMACISTS CAN WALK AND ATTORNEYS CHEW!!!

Zyesami (Aviptadil) is a formulation of synthetic human Vasoactive Intestinal Peptide (VIP), which was first discovered in 1970. NRx was the first to formulate aviptadil for human intravenous and inhaled use under the "Good Manufacturing Practices" standards in 2020.

VIP is known to target the VPAC1 receptor of the alveolar type II (ATII) cell and protect that cell against all manner of injuries, including smoke inhalation, exposure to stomach acid, and exposure to infectious agents. In addition, VIP prevents apoptosis, blocks cytokines, lowers TNFa levels, reverses CD4/CD8 ratio, and reduces cough and dyspnea in nonclinical and clinical studies.

Although first identified in the intestinal tract, VIP is now known to be produced throughout the body and primarily concentrated in the lungs. In addition, VIP has been shown in more than hundreds of peer-reviewed studies to have potent anti-inflammatory/anti-cytokine activity in animal models of respiratory distress, acute lung injury, and inflammation says the company.

https://www.precisionvaccinations.com/vaccines/zyesami-aviptadil-covid-19-therapeutic